Table 2. Hazard ratios for death from breast cancer and all causes in women aged 70 years and over and women with high comorbidity.
Real world evidence method | N | Breast cancer death | Death from any cause | ||||
---|---|---|---|---|---|---|---|
Deaths | HR | 95% CI | Deaths | HR | 95% CI | ||
Reference1 | 0.71 | 0.62–0.83 | 0.83 | 0.73–0.94 | |||
Women aged ≥70 years | |||||||
PSM | 1,298 | 431 | 0.78 | 0.64–0.95 | 568 | 0.71 | 0.60–0.85 |
IV1 | 9,653 | 1,935 | 0.57 | 0.42–0.74 | 3,953 | 0.61 | 0.49–0.74 |
IV2 | 9,653 | 1,935 | 0.57 | 0.42–0.73 | 3,953 | 0.63 | 0.50–0.76 |
Women with high comorbidity | |||||||
PSM | 2,034 | 254 | 0.67 | 0.51–0.86 | 421 | 0.67 | 0.56–0.82 |
IV1 | 7,965 | 740 | 0.68 | 0.42–1.10 | 1,388 | 0.92 | 0.63–1.33 |
IV2 | 7,965 | 740 | 0.59 | 0.37–0.99 | 1,388 | 0.82 | 0.58–1.22 |
1Early Breast Cancer Trialists’ Collaborative Group meta-analysis of newer anthracycline-containing regimens versus placebo [2].
IV, instrumental variable; PSM, propensity score matching.